Sign In
Buy AUPH
$15.67
+0.280 (+1.82%)
At Close: Jun 03, 2026
Aurinia: A Commercial Stage Company With Major Headwinds
04:44am, Sunday, 06'th Nov 2022
Aurinia has been facing many problems. Potential sales chatter may be a result of its problems.
What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals
07:13pm, Friday, 04'th Nov 2022 Benzinga
Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
0
0
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
02:41pm, Friday, 04'th Nov 2022 Benzinga
Upgrades
Citigroup upgraded the previous rating for Advanced Energy Industries Inc (NASDAQ:AEIS) from Neutral to Buy. For the third quarter, Advanced Energy Indus had an EPS of $2.12, compared to yea
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
08:41am, Friday, 04'th Nov 2022 Benzinga
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.
Acutus
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
06:35pm, Thursday, 03'rd Nov 2022 Benzinga
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.
Virax Biolabs Group Limited (NASDAQ: VRAX) surged 34% to $2.25 after the company announced the distribution of a RSV-I
Aurinia Pharmaceuticals Inc. (AUPH) Q3 2022 Earnings Call Transcript
11:53am, Thursday, 03'rd Nov 2022
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief F
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
11:25am, Thursday, 03'rd Nov 2022 Zacks Investment Research
Aurinia (AUPH) delivered earnings and revenue surprises of 66.67% and 46.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
09:02am, Thursday, 03'rd Nov 2022
Aurinia (AUPH) delivered earnings and revenue surprises of 66.67% and 46.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
05:30pm, Friday, 28'th Oct 2022
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third quart
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
09:37am, Monday, 24'th Oct 2022 Benzinga
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday.
Altamira Therapeutics Ltd. (NASDAQ: CYTO) climbed 58.6% to close at $0.5197 on Friday after the c
Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?
01:12pm, Friday, 21'st Oct 2022 Zacks Investment Research
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Aurinia (AUPH) Moves 13.1% Higher: Will This Strength Last?
10:32am, Friday, 21'st Oct 2022
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval
04:04pm, Tuesday, 20'th Sep 2022 Zacks Investment Research
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
Aurinia's (AUPH) Oral Lupus Drug Lupkynis Gets European Approval
01:33pm, Tuesday, 20'th Sep 2022
Aurinia Pharmaceutical (AUPH) receives marketing authorization from the European Union for its orally administered CNI immunosuppressant, Lupkynis, for treating lupus nephritis.
Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
11:53am, Monday, 15'th Aug 2022
LUPKYNIS revenues and company net losses are tracking better than my valuation model predicts -- and new European revenues are on the horizon. However, expenses continue to rise, which is contrary to
